New insider Huang Lan claimed ownership of 737,342 units of Ordinary Shares (SEC Form 3)

$BYSI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BYSI alert in real time by email
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Huang Lan

(Last) (First) (Middle)
C/O BEYONDSPRING INC., 100 CAMPUS DRIVE
WEST SIDE, 4TH FLOOR, SUITE 410

(Street)
FLORHAM PARK NJ 07932

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/31/2024
3. Issuer Name and Ticker or Trading Symbol
BeyondSpring Inc. [ BYSI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 2 I By Ever Regal Group Limited(1)
Ordinary Shares 1 I By Fairy Eagle Investments Limited(2)
Ordinary Shares 1 I By Rosy Time Holdings Limited(3)
Ordinary Shares 323,702(4) I By Lan Huang 2022 Grantor Retained Annuity Trust
Ordinary Shares 413,636(5) I By 2024 SPIRIT GRAT
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) (6) 08/01/2030 Ordinary Shares 460,000 $11.03(6) D
Stock Options (right to buy) (7) 01/11/2032 Ordinary Shares 90,343 $4.69(7) D
Stock Options (right to buy) (8) 05/08/2033 Ordinary Shares 400,000 $0.9835(8) D
Stock Options (right to buy) (9) 03/19/2034 Ordinary Shares 33,663 $3.168(9) D
Explanation of Responses:
1. The reporting person is the sole owner of Ever Regal Group Limited.
2. The reporting person's spouse is the sole owner of Fairy Eagle Investments Limited.
3. The reporting person's spouse is the sole owner of Rosy Time Holdings Limited.
4. Reflects shares held by the Lan Huang 2022 Grantor Retained Annuity Trust (the "2022 GRAT") for the benefit of Dr. Lan Huang's children. Dr. Lan Huang is trustee of the 2022 GRAT.
5. Reflects shares held by the 2024 SPIRIT GRAT for the benefit of Dr. Lan Huang's children. Dr. Lan Huang is trustee of the 2024 SPIRIT GRAT.
6. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. 388,000 of the stock options are fully vested and exercisable. 72,000 of the stock options will vest on December 31, 2024.
7. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All 90,343 stock options are fully vested and exercisable.
8. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. 133,333 of the stock options are fully vested and exercisable. 133,333 of the stock options will vest on May 8, 2025, and 133,334 of the stock options will vest on May 8, 2026.
9. Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. 11,221 of the stock options are fully vested and exercisable. 11,221 of the stock options will vest on December 31, 2024, and 11,221 of the stock options will vest on June 30, 2025.
/s/ Lan Huang 12/31/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $BYSI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BYSI

DatePrice TargetRatingAnalyst
12/2/2021$38.00 → $5.00Buy → Hold
Jefferies
12/2/2021$45.00 → $5.00Buy → Underperform
B of A Securities
12/1/2021Outperform → Mkt Perform
William Blair
12/1/2021Buy → Neutral
H.C. Wainwright
9/20/2021$100.00 → $65.00Buy
HC Wainwright & Co.
9/9/2021$50.00Outperform
Robert W. Baird
9/9/2021$50.00Outperform
Baird
8/4/2021$100.00Neutral → Buy
HC Wainwright & Co.
More analyst ratings

$BYSI
Press Releases

Fastest customizable press release news feed in the world

See more
  • BeyondSpring Files 2024 Annual Report on Form 10-K

    FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section. The Company will provide

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

    Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

    KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED's ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted solid tumor indications. SEED is advancing ST-01156 toward an Investigational New Drug (IND) application, with an expected IND filing in the first half of 2025. The Rare Pediatric Disease designation

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BYSI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BYSI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BYSI
SEC Filings

See more

$BYSI
Leadership Updates

Live Leadership Updates

See more
  • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

    Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

    SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

    $BYSI
    $CPRX
    $OPNT
    $PALI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$BYSI
Financials

Live finance-specific insights

See more
  • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

    Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

    FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

    New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor

    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BYSI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more